Novel pipeline therapies to drive diabetic neuropathic pain market across 7MM to $3 bn in 2031:… EP News Bureau Feb 24, 2023 The growth will be driven by the potential introduction of four promising late-stage pipeline products and an increase in the…
Evotec receives €3 million payment for Bayer starting phase-II clinical development of DNP programme EP News Bureau Mar 22, 2022 The phase-II study is anticipated to run until the end of 2022
